Insider Selling: Corcept Therapeutics (NASDAQ:CORT) Insider Sells $296,305.67 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 8,233 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total value of $296,305.67. Following the completion of the transaction, the insider owned 2,231 shares in the company, valued at $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

William Guyer also recently made the following trade(s):

• On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00.
• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $33.87 on Monday. The stock’s 50-day moving average is $39.59 and its 200 day moving average is $64.39. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of 41.31 and a beta of 0.29. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $117.33. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.26 earnings per share. On average, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: COR T’s Korlym revenue momentum: Zacks highlights a 13% Y/Y sales rise for Korlym in 2025 and projects 2026 revenue of $900M–$1B, suggesting solid underlying product sales even as competitive and legal risks persist. Korlym revenue article
• Neutral Sentiment: Short‑interest data published for early March appears inconsistent/zero (likely a data/reporting glitch) and does not provide clear evidence of increased shorting pressure at this time — investors should treat those figures cautiously. (Multiple short‑interest entries in news feed showed 0 shares / NaN changes.)
• Negative Sentiment: Hagens Berman and other firms: A securities class action (Allegheny County Employees’ Retirement System v. Corcept et al.) was flagged this week alleging the company and executives misled investors, citing FDA warnings and “evidence gaps” around the Relacorilant NDA that previously triggered a ~50% stock drop. Lead‑plaintiff deadline is April 21, 2026. Hagens Berman notice
• Negative Sentiment: Multiple plaintiff firms (Bronstein, Rosen, Pomerantz, Schall, Glancy, DJS, ClaimsFiler, etc.) have issued alerts encouraging investors to join/lead the class action based on purchases between Oct 31, 2024 and Dec 30, 2025 — this amplifies media attention and could increase settlement/defense costs and management distraction. Example: Bronstein notice. Bronstein notice
• Negative Sentiment: Schall/Rosen/Pomerantz & others reiterate class‑period and April 21 deadline; aggregated press releases increase likelihood of large plaintiff turnout and publicity — a material near‑term catalyst pressuring the stock. Example: Schall Law Firm reminder. Schall Law Firm notice

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC bought a new position in shares of Corcept Therapeutics in the fourth quarter worth about $25,000. Advisory Services Network LLC bought a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC raised its stake in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares during the period. Golden State Wealth Management LLC bought a new position in Corcept Therapeutics in the 2nd quarter worth approximately $28,000. Finally, Atlas Capital Advisors Inc. purchased a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research note on Wednesday, December 31st. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. HC Wainwright reduced their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research note on Wednesday, December 31st. Finally, UBS Group started coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price target for the company. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $77.17.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.